Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells

IN SIK KIM, EUN-JU YANG, DONG-HA SHIN, KWANG-HEE SON, HO-YONG PARK and JI-SOOK LEE

1Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301-746; 2Department of Clinical Laboratory Science, College of Health and Therapy, Daegu Hany University, Gyeongsan 712-715; 3Insect Biotech Co., Ltd., Dajeon 305-811; 4Industrial Bio-material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806; 5Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan, Chonbuk 570-750, Republic of Korea

DOI: 10.3892/mmr_xxxxxxxx

Abstract. Arazyme is a novel extracellular metalloprotease secreted by Aranicola proteolytica. Endothelial cells are involved in the pathogenesis of a number of inflammatory diseases, induce uncontrolled cell viability and express various inflammatory mediators, including cytokines, chemokines, adhesion molecules and reactive oxygen species (ROS). In the current study, human umbilical vein endothelial cells (HUVECs) were used to investigate the anti-inflammatory effects of arazyme following lipopolysaccharide (LPS) stimulation. Apoptosis of HUVECs due to LPS was inhibited by arazyme. In various inflammatory responses induced by LPS, arazyme inhibited the secretion of the monocyte chemoattractant protein-1 and interleukin-6, and the expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. Arazyme also suppressed ROS production in HUVECs. The action of arazyme was not associated with NF-κB activity in HUVECs. These results indicate that arazyme has anti-inflammatory properties in inflamed endothelial cells and may be useful as a therapeutic agent for inflammatory diseases associated with endothelial cells.

Introduction

Arazyme is a novel extracellular metalloprotease produced by Aranicola proteolytica (also known as Serratia proteamaraculans), an aerobic Gram negative symbiotic bacterium isolated from the intestine of the spider, Nephila clavata (1,2). A previous report demonstrated that arazyme has hepatoprotective activity against carbon tetrachloride-induced hepatic injury and that the mechanism involves increased expression of SMP30 and antioxidant proteins (3).

Human umbilical vein endothelial cells (HUVECs) are used in studies of various diseases, including angiogenesis, atherosclerosis and the inflammatory process. Notably, HUVECs are involved in the release of cytokines and chemokines, as well as cell migration during the inflammatory process (4,5). Increased levels of vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) are early markers of endothelial activation and dysfunction in inflammatory diseases (6). Activation of adhesion molecules on the surface of endothelial cells induces leukocyte migration and leads to inflammation (7). The HUVEC-associated inflammatory response is induced by a variety of inflammatory mediators, including lipopolysaccharide (LPS), tumor necrosis factor-α and oxidized-low density lipoprotein (6,8,9). LPS is an integral part of the bacterial outer membrane and is a significant stimulator of inflammation. LPS induces the generation of reactive oxygen species (ROS) and upregulates cytokines, chemokines and adhesion molecules in HUVECs (5). These mechanisms contribute to endothelial dysfunction and may evoke endothelial cell-associated diseases. A number of studies have attempted to identify methods to protect against the inflammatory response and endothelial cell death (9-11). In the current study, the role of arazyme in the LPS-mediated inflammatory response in HUVECs was investigated.

Materials and methods

Reagents. Endothelial cell basal medium-2 (EBM-2), fetal bovine serum (FBS), recombinant human fibroblast growth factor (rhFGF), recombinant human epidermal growth factor (rhEGF), hydrocortisone, gentamicin sulfate, amphotericin-B (GA-1000), heparin, vascular endothelial growth factor (VEGF), ascorbic acid and long R insulin-like growth factor-1 (RIGF-1) were purchased from Lonza (Walkersville, MD, USA). Trypsin-EDTA was purchased from Life Technologies, Inc. (Gaithersburg, MD, USA). LPS was purchased from Sigma-Aldrich Korea (Seoul, Korea).
2',7'-dichlorofluorescein diacetate (DCFDA) and Alexa Fluor® Probes (Eugene, OR, USA). Normal rabbit IgG, anti-VCAM-1 and anti-ICAM-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Enzyme purification. Arazyme was purified as described previously (2). Briefly, extracellular fractions were collected by centrifugation of the culture medium or by filtration using a 0.2-µm membrane filter (Pall Life Sciences, Port Washington, NY, USA). Chromatography was performed on a DEAE-cellulose column equilibrated with 50 mM potassium phosphate buffer (pH 7.6). Bound proteins were eluted with a 0.1-0.5 M sodium chloride gradient at a flow rate of 400 ml/h and each fraction was concentrated with a 10 kD cassette membrane (Pall Life Sciences). The protein solution was then loaded at a flow rate of 20 ml/h onto a Sephadex G-75 column (GE Healthcare Life Sciences, Pittsburgh, PA, USA) equilibrated previously with 50 mM potassium phosphate buffer (pH 7.8). Fractions containing proteolytic activity were concentrated with the 10 kD cassette membrane and stored at -20°C.

Cell culture. HUVECs were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured on 0.2% gelatin-coated flasks with EBM-2 medium supplemented with 2% FBS, rhFGF, rhEGF, hydrocortisone, GA-1000, heparin, VEGF, ascorbic acid and R3-IGF-1. HUVECs were incubated at 37°C in a 5% CO2 incubator.

MTT assay. The MTT assay was performed with a cell proliferation kit (Roche Diagnostics, Mannheim, Germany) to determine cell viability. HUVECs at a concentration of 5x104 cells/100 µl were plated on a 96-well plate. Following arazyme treatment, the plate was incubated for 24 h at 37°C in a 5% CO2 incubator. Next, 10 µl MTT solution was added to each well and the plate was incubated at 37°C for 4 h in a CO2 incubator. A 100 µl aliquot of solubilization solution was added to each well. Following 24 h incubation, the absorbance was measured at 550 nm using an enzyme-linked immunosorbent assay (ELISA) reader (Bio-Tek Instruments Inc., Winooski, VT, USA).

Cell apoptosis. An Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection kit (BD Biosciences, San Jose, CA, USA) was used to detect apoptosis. Following a 24 h treatment with stimulators, including LPS and arazyme, HUVECs were incubated with the FITC-labeled Annexin V and propidium iodide (PI) for 15 min at room temperature. Apoptotic cells were analyzed by flow cytometry using CellQuest software (BD Biosciences) and were defined as cells in the right quadrant, which stained positive for Annexin V with/without PI. A total of 10,000 events were collected for each sample.

ELISA. HUVECs were treated with LPS for 24 h and the supernatants were collected. The concentrations of monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) were measured in the cell supernatant with a sandwich ELISA (OptEIA™ Set human IL-6 and MCP-1; BD Biosciences) according to the manufacturer's instructions. The concentration of each protein was calculated from standard curves.

Results

Arazyme inhibits HUVEC apoptosis induced by LPS. Prior to examining the effect of arazyme on HUVECs, the effect of arazyme on cell viability was examined. As shown in Fig. 1, the survival rate of HUVECs was not altered by arazyme treatment at concentrations of 1, 5, 10 or 20 µg/ml. Thus, 20 µg/ml arazyme was used to determine the anti-inflammatory effects. Since LPS causes endothelial injury by inducing apoptosis, the...
protective effect of arazyme on LPS-induced apoptosis was determined (12). As shown in Fig. 2, treatment with 10 µg/ml LPS led to strong induction of apoptosis in HUVECs. Arazyme significantly blocked LPS-induced apoptosis of HUVECs.

Arazyme decreases secretion of monocyte chemoattractant protein-1 (MCP-1) and IL-6 in HUVECs. To determine the inhibitory effect of arazyme on cytokine release from HUVECs, MCP-1 and IL-6 levels were measured by ELISA in HUVEC supernatants following treatment with 10 µg/ml LPS in the presence or absence of arazyme. Arazyme decreased MCP-1 secretion considerably in HUVECs stimulated with LPS (Fig. 3A). The release of IL-6 in LPS-stimulated HUVECs tended to be inhibited by arazyme, but the difference was not significant (Fig. 3B). These observations indicate that arazyme has anti-inflammatory effects on LPS-stimulated HUVECs by suppressing cytokine release.

Arazyme inhibits expression of adhesion molecules in HUVECs. LPS increases cell adhesion molecules, including VCAM-1 and ICAM-1 in HUVECs (13,14). To determine other anti-inflammatory effects of arazyme, its effect on VCAM-1 and ICAM-1 expression induced by LPS was investigated. HUVECs were pretreated with 10 µg/ml arazyme for 1 h and...
Arazyme inhibited MCP-1 expression, and a strong inducer of ROS production in HUVECs. Pre-incubating HUVECs with arazyme suppressed ROS generation due to LPS. This result indicates that arazyme produces an anti-inflammatory effect by suppressing oxidative stress.

**Discussion**

Although arazyme has a protective effect against hepatic injury, other protective and therapeutic functions, including anti-inflammatory, have not yet been reported (3). Previous studies have identified novel inhibitory materials against the inflammatory response in endothelial cells such as Ecklonia cava extracts and cilostazol (9,11). The current study, focused on elucidating the effect of arazyme on the inflammatory response in endothelial cells such as HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide; con, control; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intracellular adhesion molecule-1.

**Figure 4.** Arazyme suppresses the expression of adhesion molecules induced by LPS in HUVECs. HUVECs were pre-treated with 20 µg/ml arazyme for 1 h and then with 10 µl/ml LPS for 24 h. Protein expression of (A) VCAM-1 and (B) ICAM-1 in HUVECs was analyzed by flow cytometry using anti-VCAM-1 and anti-ICAM-1 antibodies. The isotype con was analyzed by incubating with normal mouse IgG. Data are presented in relation to the isotype control, which was set to 100%. **P<0.05 and ***P<0.01, the untreated group vs. the LPS-treated group or the LPS-treated group vs. the arazyme-treated group. HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide; con, control; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intracellular adhesion molecule-1.

**Figure 5.** Arazyme is not involved in NF-κB activation in HUVECs. Following HUVEC pre-treatment with arazyme for 1 h, the cells were treated with 10 µg/ml LPS for 24 h and collected to determine NF-κB activation. The nuclear fraction was extracted and NF-κB DNA binding activity was assessed using an EZ-Detect™ Transcription Factor kit. All data are expressed as the mean ± standard error of the mean of three independent experiments. **P<0.01, the untreated group vs. the LPS-treated group or the LPS-treated group vs. the arazyme-treated group. NF-κB, nuclear factor-κB; HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide.

**Figure 6.** Arazyme reduces ROS production in LPS-stimulated HUVECs. HUVECs were pretreated with 20 µg/ml arazyme for 1 h and then with 10 µg/ml LPS for 4 h. Following LPS stimulation, the HUVECs were incubated for 10 min with phosphate-buffered saline containing 3.3 µM 2',7'-dichlorofluorescein diacetate and observed by flow cytometry analysis. The results are expressed as the mean ± standard error of the mean of ten independent experiments. **P<0.05 and ***P<0.01, the untreated group vs. the LPS-treated group or the LPS-treated group vs. the arazyme-treated group. ROS, reactive oxygen species; HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide.
inflammation by inhibiting spontaneous apoptosis in neutrophils (17). IL-6 is a multipotent cytokine and increases the proliferation and differentiation of numerous cell types, including B cells and skin cells (18). IL-6 induces a shift from acute- to chronic-phase inflammation, including that observed in allergic diseases (19,20). Arayme also inhibited the expression of VCAM-1 and ICAM-1 increased by LPS. VCAM-1 and ICAM-1 function as adhesion molecules and initiators of the inflammatory signaling pathway (5). These results indicate that arayme acts as an anti-inflammatory agent in HUVECs.

ROS are generated at sites of inflammation and cause cellular injury and death (4). HUVECs modulate the movement of macromolecules and circulating immune cells from the blood into tissue. Increased oxidative stress in HUVECs induces vascular endothelial permeability and enhances leukocyte adhesion. Since arayme suppresses ROS production due to LPS, arayme may act as an inhibitor of inflammatory cell migration into tissue. Since hyperproduction of ROS induces cell death mediated by cytotoxicity, the anti-apoptotic effect of arayme was hypothesized in HUVECs (21). The experimental results may indicate the validity of this hypothesis, despite the lack of a direct association between ROS and cell death.

A variety of inflammatory mediators, including LPS and ROS activate NF-xB and then induce an increase in adhesion molecules and the secretion of cytokines and chemokines (21).

To examine the arayme mechanism, NF-xB activation was evaluated. However, arayme did not inhibit NF-xB activation caused by LPS stimulation. Although the mechanism underlying the effects of arayme has not been previously determined, a hypothetical mechanism for the anti-apoptotic and anti-inflammatory effects may be suggested since arayme is a metalloprotease. Arayme may mediate its anti-apoptotic or anti-inflammatory functions via the protease-activated receptor (PAR), which is a G-protein-coupled receptor or through an unidentified receptor (22). PAR or an unknown-mediated signal, may be associated with inhibiting the LPS-induced signal. Secondly, arayme may directly cleave cytokines, including MCP-1 and IL-6 and adhesion molecules, since it may hydrolyze pro-inflammatory molecules, including bradykinin and histamine (23,24).

The exact mechanism of action of arayme remains to be determined and further studies are being conducted to investigate more complex mechanisms.

In conclusion, arayme has anti-inflammatory effects in HUVECs that include suppression of cell apoptosis, ROS production, and expression of IL-6, MCP-1, VCAM-1 and ICAM-1. Arayme may be a useful agent to treat endothelial dysfunction-associated diseases, including atherosclerosis and cardiovascular diseases.

Acknowledgements

This study was supported by a grant from the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program.

References


